Testing Documentation
Supplier-Provided Analytical Reports
The reports below correspond to the listed product codes, strengths, and testing dates. They include identity, purity, and measured-content data where provided.
Important disclosure: These reports were supplied by the manufacturer and were not independently commissioned by Ironclad Peptide Labs. Most reports state that the issuing laboratory does not hold CMA/CNAS accreditation and that the documents do not carry legal certification validity. A report reflects only the tested sample and should not be read as FDA approval, proof of safety, or authorization for human use. Products are intended for research use only.
| Product | Report / Lot | Test date | Reported result | Report |
|---|---|---|---|---|
| Adamax 10 mg | AX10-20260911S5817 | September 11, 2026 | 99.88% purity; 9.86 mg | View PDF |
| ARA-290 10 mg | RA10-20260911S5817 | September 11, 2026 | 99.69% purity; 12.99 mg | View PDF |
| BPC-157 10 mg | BC10 2-20260831S8989 | September 1, 2026 | 99.87% purity; 12.08 mg; identity detected | View PDF |
| DSIP 10 mg | DS10-20260822S2002 | August 22, 2026 | 99.88% purity; 10.08 mg | View PDF |
| Epithalon 10 mg | ET10-20260910S9112 | September 11, 2026 | 99.82% purity; 13.39 mg | View PDF |
| GHK-Cu 50 mg | CU50-20260910S9112 | September 11, 2026 | 99.95% purity; 51.43 mg | View PDF |
| IGF-1 LR3 1 mg | IG1-20260910S9112 | September 11, 2026 | 99.65% purity; 1.08 mg | View PDF |
| KPV 10 mg | KPV10-0902 | September 17, 2026 | 99.71% purity; 9.41 mg; identity confirmed | View PDF |
| MOTS-C 10 mg | MS10-20260822S2002 | August 22, 2026 | 99.60% purity; 10.38 mg; identity detected | View PDF |
| MOTS-C 20 mg | MS20-20260911S5817 | September 11, 2026 | 99.89% purity; 22.59 mg | View PDF |
| PT-141 10 mg | P41-0901 | September 17, 2026 | 99.77% purity; 11.90 mg; identity confirmed | View PDF |
| Retatrutide (IPL3) 10 mg | RT10-20260822S2002 | August 22, 2026 | 99.88% purity; 11.87 mg; identity detected | View PDF |
| Retatrutide (IPL3) 20 mg | RT20-20260911S5817 | September 11, 2026 | 99.65% purity; 23.21 mg | View PDF |
| Retatrutide (IPL3) 30 mg | RT30-20260910S9112 | September 11, 2026 | 99.87% purity; 33.01 mg | View PDF |
| Semax 10 mg | XA10-20260817S0750 | August 19, 2026 | 99.79% purity; 10.56 mg; identity detected | View PDF |
| TB-500 10 mg | TB10-0902 | September 17, 2026 | 99.36% purity; 10.23 mg; identity confirmed | View PDF |
| Tesamorelin (Teza) 10 mg | TSM10-0902 | September 17, 2026 | 99.12% purity; 10.88 mg; identity confirmed | View PDF |
| GHK-Cu 100 mg | CU100-20260817S0750 | August 18, 2026 | 99.80% purity; 98.96 mg; identity detected | View PDF |
| TB-500 5 mg | TB5-20260906S9211 | September 5, 2026 | 99.27% purity; 6.27 mg; identity detected | View PDF |
| Tesamorelin (Teza) 20 mg | TSM20-20260825S6601 | August 26, 2026 | 99.73% purity; 22.01 mg; identity detected | View PDF |
| Wolverine Stack 20 mg | BB20-20260810S4420 | August 10, 2026 | 99.76% combined purity; BPC-157 12.48 mg; TB4 10.82 mg; identity detected | View PDF |
Questions about a report or product code? Contact Ironclad Peptide Labs before ordering.